Calls for New Projects in Chemical Biology and Drug Discovery
September 8, 2026 @ 11:00 – 12:00 CEST
The Chemical Biology Consortium Sweden (CBCS) and the Drug Discovery and Development (DDD) Platform at SciLifeLab invite researchers to submit proposals for new collaborative projects.
Chemical biology projects
The Chemical Biology unit (CBCS) welcomes projects involving:
- Assay development for small-molecule screening
- Phenotypic and target-based screening and in silico – virtual screening support
- Enabling chemistry, including medicinal and computational chemistry
- Drug profiling projects in advanced cell models (patient derived material and 3D cultures)
Many of the projects supported by CBCS involve phenotypic screening addressing basic research, disease biology but also projects outside human health. Further information is available at www.cbcs.se.
Drug discovery & Development projects
The DDD Platform invites proposals addressing a clearly defined unmet medical need and offering a credible route toward commercialisation. Projects involving any therapeutic modality that can be developed in collaboration with DDD are welcome, including:
- Small molecules
- Antibodies
- Oligonucleotides
- Emerging therapeutic modalities
This year’s call introduces a joint opportunity supported by CBCS, DDD and MAX IV.
New opportunity: Enabling Drug Discovery (EDD)
Through the Enabling Drug Discovery (EDD) initiative, the combined capabilities of SciLifeLab DDD, CBCS and MAX IV offer academic researchers an integrated workflow for early-stage target based drug discovery. The support includes expert support on assay design, technology transfer and hit verification, together with access to complementary discovery approaches such as:
- AI-assisted in silico screening for small molecules
- High-throughput screening (HTS) for small molecules
- Selection for small molecule binders from DNA-encoded compound libraries (DEL)
- Fragment screening (crystallographic screening at MAX IV and by NMR at CBCS)
- Selection for human antibody fragments from Phage display libraries
- Design and synthesis of custom-made oligonucleotide libraries
Principal investigators who successfully co-develop and validate suitable assays will be offered the opportunity to screen for potential therapeutic candidates. The resulting hits and data can provide a strong foundation for further scientific investigation and subsequent applications to SciLifeLab’s CBCS and Drug Discovery and Development (DDD) platforms.
Google Calendar 
